Seenthis
•
 
Identifiants personnels
  • [mot de passe oublié ?]

  • http://www.nejm.org
  • /na101
  • /home
  • /literatum
  • /publisher
  • /mms
  • /journals
  • /content
  • /nejm
  • /2017
  • /nejm_2017.376.issue-22
  • /nejmc1700150
  • /20170531
  • /images

/medium

  • ►/nejmc1700150_f1.gif
  • @fil
    Fil @fil 1/06/2017
    4
    @cocoadaemon
    @lyco
    @unagi
    @sinehebdo
    4

    A 1980 Letter on the Risk of Opioid Addiction — NEJM
    ▻http://www.nejm.org/doi/full/10.1056/NEJMc1700150

    http://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2017/nejm_2017.376.issue-22/nejmc1700150/20170531/images/medium/nejmc1700150_f1.gif

    We identified 608 citations of the index publication and noted a sizable increase after the introduction of OxyContin (a long-acting formulation of oxycodone) in 1995 (Figure 1FIGURE 1
    Number and Type of Citations of the 1980 Letter, According to Year.). Of the articles that included a reference to the 1980 letter, the authors of 439 (72.2%) cited it as evidence that addiction was rare in patients treated with opioids. Of the 608 articles, the authors of 491 articles (80.8%) did not note that the patients who were described in the letter were hospitalized at the time they received the prescription, whereas some authors grossly misrepresented the conclusions of the letter

    On a donc les noms de 608 auteurs (et plus) qui ont participé par la #désinformation médicale à la prolifération des #opiacés qui aboutit à la #crise_sanitaire actuelle.

    #recherche #bibliométrie #médecine #drogues #États-Unis #pharma

    • #OxyContin
    Fil @fil
    • @cocoadaemon
      alban @cocoadaemon 1/06/2017

      In conclusion, we found that a five-sentence letter published in the Journal in 1980 was heavily and uncritically cited as evidence that addiction was rare with long-term opioid therapy. We believe that this citation pattern contributed to the North American opioid crisis by helping to shape a narrative that allayed prescribers’ concerns about the risk of addiction associated with long-term opioid therapy. In 2007, the manufacturer of OxyContin and three senior executives pleaded guilty to federal criminal charges that they misled regulators, doctors, and patients about the risk of addiction associated with the drug.5 Our findings highlight the potential consequences of inaccurate citation and underscore the need for diligence when citing previously published studies.

      alban @cocoadaemon
    • @sinehebdo
      Dror@sinehebdo @sinehebdo 1/06/2017

      voir aussi #Fentanyl la drogue qui a tué #Prince et plein d’anonymes...

      Dror@sinehebdo @sinehebdo
    Écrire un commentaire